INS and Insulin resistance: Increased plasma acylcarnitines levels have been reported in insulin-resistant and T2DM subjects as products of incomplete or inefficient β-oxidation, and tissue accumulation of acylcarnitine molecules may lead to activation of proinflammatory pathways, which are implicated in insulin resistance and T2DM development [41].